AstraZeneca divests some drugs to Atnahs Pharma
Topics: ASTRAZENECA DRUGS ATNAHS PHARMA
Under the terms of the agreement, AstraZeneca has received a payment of $350m from Atnahs.
The company may also receive future sales-contingent payments of up to $40m between 2020 and 2022.
The upfront payment will be reported in AstraZeneca’s financial statements within Other Operating Income and Expense in the first quarter of 2020. ■